|  |  | 

India Top Headlines

India Will Have Covid Vaccine ‘Approved’ By First Quarter 2021: Report | India News


NEW YORK: India is on track for “approval” vaccine within the first quarter of calendar year 2021 and the Pune-based Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, is well placed to offer the first vaccineaccording to a report released Thursday by Bernstein Research, one of Wall Street’s leading research and brokerage firms.
“Globally, there are four candidates that are close to being approved by the end of CY2020 or early 2021. Through partnerships, India has access to two of them: the AZ / Oxford viral vector. vaccine and the Novavax protein subunit vaccine with AZ / Oxford’s vaccine a quarter advantage, “says the Bernstein report, which has been reviewed by IANS.
“With its existing capabilities and capabilities, SII is better positioned to commercialize one or both of the partners vaccine candidates based on approval time, capabilities, and pricing. ”
The data from the phase 1 and phase trials appear promising for both candidates “in terms of safety and the ability of the vaccines to elicit an immune response.” As things look now, the report indicates that both vaccine candidates “will require two doses to be administered 21/28 days apart.”
The report lends an optimistic tone to India’s “global capacity equation” and does not foresee “challenges of upscaling manufacturing.”
Serum Institute of India, the report says, could supply 600 million doses in 2021 and 1 billion doses in 2022, of which 400 to 500 million “should be available in India by 2021” in the context of the company’s commitments. with Gavi. Vaccine Alliance and low and middle income markets.
The report estimates that vaccine volumes will be split 55:45 between the public and private market.
“We believe that the government channel will have access to capacities first, but we also believe that there will be a sizeable private market. In terms of financing, labor and delivery infrastructure, the government will have a difficult time shouldering the load on its own and we hope than the private market to intervene and complement “.
The SII has announced that Gavi will purchase vaccines at $ 3 per dose. The Bernstein report uses that as a benchmark to estimate the acquisition price at around $ 3 per dose for the government and the final consumer price at around $ 6 per dose.
Apart from IBS, the report lists at least three other Indian pharmaceutical companies: Zydus, Bharat Biotech and Biological E – who are working on their own vaccine candidates and are currently in Phase 1 and 2.
Between IBS, Bharat Biotech, Biological E, and a few smaller players, India produces around 2.3 billion doses of various vaccines each year.
Only IBS is the world’s largest manufacturer of vaccines with a capacity of 1.5 billion doses. Every two out of every three children worldwide receives a manufactured vaccine for IBS.
In early August, SII partnered with Gavi, The Vaccine Alliance and the Bill and Melinda Gates Foundation, to accelerate the manufacturing and delivery of up to 100 million doses of COVID-19 vaccines for India and Low- and Middle-Income Countries (LMICs).
The collaboration injects seed capital into SII to help them increase manufacturing capacity now so that, once vaccine, or vaccines, gets regulatory approval and WHO prequalification, doses can be produced at scale for distribution in India and low- and middle-income countries as early as the first half of 2021.
The general vaccine The Indian market is estimated at “$ 6 billion spread over fiscal year 21-22,” according to Bernstein.

Original source